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Abstract
It has been long recognized that the mammalian heart loses its proliferative capacity soon after 
birth, yet, the molecular basis of this loss of cardiac proliferation postnatally is largely unknown. 
In this study, we found that cardiac ErbB2, a member of the epidermal growth factor receptor 
family, exhibits a rapid and dramatic decline in expression at the neonatal stage. We further 
demonstrate that conditional ablation of ErbB2 in the ventricular myocardium results in 
upregulation of negative cell cycle regulators and a significant reduction in cardiomyocyte 
proliferation during the narrow neonatal proliferative time window. Together, our data reveal a 
positive correlation between the expression levels of ErbB2 with neonatal cardiomyocyte 
proliferation and suggest that reduction in cardiac ErbB2 expression may contribute to the loss of 
postnatal cardiomyocyte proliferative capacity.
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1. Introduction
Cardiovascular diseases are the leading causes of morbidity and mortality worldwide. In 
contrast to lower vertebrates and neonatal mammals (Poss et al., 2002; Porrello et al., 
2011b), the adult mammals exhibit limited cardiac regenerative capacity (Laflamme and 
Murry, 2011), and are therefore susceptible to massive cardiomyocyte (CM) loss due to 
myocardial infarction and subsequent adverse remodeling. To address this issue, a number of 
experimental strategies have been developed to restore functional myocardium; these include 
cell therapy approach that utilizes diverse cell types such as embryonic stem cells, induced 
pluripotent stem cells, cardiac progenitor cells to regenerate functional CMs in injured 
hearts. An alternative approach involves directly converting resident cardiac fibroblasts into 
functional CMs in vivo by forced expression of the cardiac reprogramming factors (Qian et 
al., 2012; Song et al., 2012). In addition, recent mouse studies have suggested that 
stimulating existing CMs to re-enter cell cycle and proliferate could be a promising strategy 
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to replenish lost CMs for regenerative purposes (Reiss et al., 1996; Zhao et al., 1998; Liao et 
al., 2001; Bersell et al., 2009; Porrello et al., 2011a; Sdek et al., 2011; Mahmoud et al., 
2013; Xin et al., 2013; Puente et al., 2014; D’Uva et al., 2015). For instance, the epidermal 
growth factor–like ligand Neuregulin1 (Nrg1) and its ErbB4/2 tyrosine kinase receptors have 
been manipulated to promote CM proliferation and cardiac regeneration (Bersell et al., 2009; 
D’Uva et al., 2015; Gemberling et al., 2015).
ERBB2 is found to be amplified or over-expressed in many cancer types, suggesting that its 
level of expression that could profoundly influence cellular behaviors should be tightly 
regulated. Nrg1/ErbB signaling also plays an important role in organ development by 
regulating multiple cellular processes, including cell migration, proliferation and 
differentiation. However, an early lethality phenotype of Nrg1, ErbB2 or ErbB4 mutant mice 
(Gassmann et al., 1995; Lee et al., 1995; Meyer and Birchmeier, 1995) has hindered a 
detailed analysis of the function for this signaling pathway in later cardiac development 
and/or homeostasis.
In this study, we show that cardiac ErbB2 exhibits a decrease in expression from E13.5 to 
adulthood with a steep decline at the neonatal stage. We further demonstrate that, in the 
absence of ErbB2, neonatal CM proliferation is significantly reduced, which is accompanied 
by an upregulation of negative cell cycle regulators. Together, our data reveals a dynamic 
expression of ErbB2 in the heart and provide evidence that ErbB2 expression level positively 
correlates with CM proliferative capacity.
2. Materials and methods
2.1. Animals
ErbB2 cardiac-specific conditional knockout mice ErbB2Cko were obtained by crossing 
ErbB2fl/fl mice and Mlc2v-Cre mice. Animal care was performed in accordance with the 
guidelines established by NIH and UNC-Chapel Hill. All mouse protocols were approved by 
UNC-Chapel Hill DLAM.
2.2. Immunohistochemistry
Murine hearts were excised and rinsed with PBS after euthanasia, fixed in 0.5% 
paraformaldehyde overnight and embedded in OCT compound. Histological section was 
performed according to the standard procedures (Ma et al., 2015). All sections were blocked 
in 10% serum for 30 min at room temperature, and then incubated with primary antibodies 
against α-Actinin (1:400, Sigma Aldrich) and Ki-67 (1:400, Abcam) or pH 3 (1:200, 
Millipore) for 1 h at room temperature. After wash with PBS plus 0.1% TritonX-100, 
sections were stained with fluorescent secondary antibodies (ThermoFisher Scientific) for 
another 1 h at room temperature followed by mounted in Vectashield with DAPI (Vector 
Laboratories). Slides were analyzed with EVOS FL cell imaging system.
2.3. Isolation of neonatal mouse CM
Primary CMs were isolated from P0 ErbB2Cko mice or their control littermates ErbB2fl/fl as 
previously described (Song et al., 2000). Ventricles were rinsed with ice-cold HBSS and 
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then minced into small pieces. All tissue pieces were transferred into glass beaker and 
subjected to 0.5 mg/ml collagenase II digestion in HBSS under constant agitation. Cell 
suspension was harvested every 10 min and replaced with fresh digestion solution. CMs 
were enriched after 2-hour cell attachment.
2.4. Western blot
Murine hearts or CMs were harvested and homogenized in RIPA buffer (89901, 
ThermoFisher Scientific) using bullet blender (Next Advance) according to the 
manufacturer’s instructions. 40 μg protein of each sample was separated by 4–12% NuPAGE 
gels (ThermoFisher Scientific) and transferred to nitrocellulose membranes. After blocked 
with 5% BSA, the membranes were incubated with primary antibodies against ErbB2 
(1:200, Santa Cruz) and Gapdh (1:1000, Cell Signaling Technology). The films were 
developed by chemiluminescent system (RPN2106, GE) and band intensities were 
quantified using ImageJ software.
2.5. qPCR
RNA was extracted from murine hearts or CMs using Trizol reagent (ThermoFisher 
Scientific) according to the manufacturer’s instructions. RT-PCR was performed with 
SuperScript III kit (ThermoFisher Scientific). qPCR was performed with SYBR Green Real-
Time PCR mater mix (ThermoFisher Scientific) following the manufacturer’s protocols.
2.6. Quantification and statistics
All data were presented as mean ± SEM. The significance of differences between groups 
was analyzed using student’s t-test or ANOVA. P < 0.05 was considered as statistically 
significant.
3. Results
3.1. ErbB2 is downregulated during heart development and postnatal stages
Accumulating evidence suggests that murine CMs are actively proliferating during 
embryonic stage but exit from cell cycle soon after birth (Walsh et al., 2010) (Fig. 1A). Since 
the level of ERBB2 expression appears to influence cell growth and proliferation, we first 
determined ErbB2 transcript levels in both fetal and postnatal hearts. To this end, we 
harvested the ventricles from mice at different developmental stages. Interestingly, ErbB2 
exhibited a progressive reduction in expression with age (Fig. 1B). ErbB2 was highly 
expressed in the ventricles at embryonic day 13.5 (E13.5). This cardiac expression decreased 
significantly by about 58% at postnatal day 0 (P0). By P7, it was further reduced to about 
15% of that at E13.5, and this low level of ErbB2 expression in the ventricles remained 
relatively unaltered from P7 to 7-month-old mice.
In CMs, ErbB4 is the receptor for endothelium derived Nrg1 and heterodimers with ErbB2 
upon activation (Zhao et al., 1998). We next determined the transcript levels of ErbB4 and 
Nrg1 in the heart. We found that although it showed a trend of decreasing expression 
overtime, ErbB4, unlike ErbB2, maintained a relatively stable expression from late 
embryonic stage through early postnatal stage (Fig. 1B). Furthermore, ErbB4 in general 
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exhibits much higher expression level of about 6–15 folds than ErbB2 depending on the 
stage (Fig. 1C). Likewise, the expression of Nrg1 decreased as the heart underwent a 
transition from hyperplastic to hypertrophic growth (Fig. 1B). Thus, the downregulation of 
Nrg1/Erbb expression in the heart correlates temporally with CM exiting from active cell 
cycle.
Previous studies suggest that murine CMs exit from active cell cycle around P3 (Walsh et al., 
2010). Concurrently, active cell cycle markers show a dramatic decrease and are barely 
detectable after P21. This cell-cycle exit is associated with an upregulation of cell cycle 
inhibitors including p21, p27 (Walsh et al., 2010). Consequently, the normal growth of the 
postnatal heart become primarily driven by CM hypertrophy rather than hyperplasia starting 
from the first week of postnatal life (Li et al., 1996). Since ErbB2 exhibits a rapid and 
dramatic decrease in expression from late embryonic stage through early postnatal stage, we 
next focused on analyzing ErbB2 protein expression at the narrow neonatal time window. As 
shown in Fig. 1D, western blot analysis revealed that ErbB2 protein expression level was 
significantly downregulated right after what was previously shown to be the transient 
neonatal regenerative period. ErbB2 was about 4-fold more abundant at P0 than at P7 and 
became barely detectable in adult ventricles (postnatal 12 weeks). These results indicate that 
ErbB2 expression at both transcript and protein levels correlates with the proliferative 
capacity of the murine hearts.
3.2. ErbB2 is required for CM proliferation in neonatal hearts
The loss of regenerative capacity of the heart corresponds with a significant decline in the 
ability of CM to re-enter cell cycle and proliferate upon injury. Thus, we wanted to 
determine if ErbB2 is required for neonatal CM proliferation. We crossed Mlc2v-Cre with 
ErbB2fl/fl mice to generate ErbB2 cardiac conditional knockout mice (ErbB2Cko). qPCR 
analysis indicated that ErbB2 expression in the ErbB2Cko CMs was significantly diminished 
compared to that in the ErbB2fl/fl control CMs (Fig. 2A), whereas ErbB4 expression 
remained unaltered in the ErbB2Cko CMs. ErbB2Cko hearts were morphologically 
indistinguishable from the littermate control hearts (data not shown), we thus wanted to 
determine if the mutant hearts could display any defects at the cellular level. To this end, we 
sectioned through ErbB2Cko and ErbB2fl/fl ventricles at P0 and counterstained the sections 
with antibodies against Ki67, a marker for all active phases of cell cycle, and phosphorylated 
histone H3 (pH 3), a maker for the onset of mitosis. Quantification of Ki67+ CMs from 
sections covering multiple layers of left ventricles revealed a significant decrease in the 
percentage of Ki67+ CMs in ErbB2Cko ventricles compared to that of ErbB2fl/fl ventricles 
(from 24.1% to 13.7%, Fig. 2B,C). Likewise, the percentage of pH 3+ CMs was also 
dramatically reduced in the ErbB2Cko hearts compared to that in the ErbB2fl/fl hearts (6.1% 
to 3.5%, Fig. 2D,E). These data suggest that ErbB2 is required for neonatal CM 
proliferation.
3.3. Altered expression of cell cycle regulators in ErbB2Cko hearts
Next, we sought to explore the molecular mechanism underlying the essential role of ErbB2 
in CM proliferation. We postulated that the expression of cell cycle regulators might be 
altered in the ErbB2-depleted CMs. To test this possibility, we selected a wide range of cell 
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cycle regulator genes including cyclins, cyclin-dependent kinases (CDKs), CDK inhibitors 
(CDKIs), and checkpoint regulators, and examined their mRNA expression in ErbB2Cko and 
control ErbB2fl/fl CMs. We freshly isolated primary CMs from both control and conditional 
mutant hearts and performed qRT-PCR to assess the expression of these cell cycle genes. Six 
out of 9 selected CDKIs, including Cdkn3, p15, p18, p19ARF, p21, and p27, exhibited 
significantly 1.4 folds to 2.7 folds upregulation in their expression in ErbB2Cko CMs (Fig. 
3A). The expression of other negative regulators of cell cycle, such as Atm, Bax, Casp3, 
Rbl1 and Trp53, were also significantly increased by >2.5 folds (Fig. 3B). In contrast, 
conditional ablation of ErbB2 in CMs resulted in changes in the expression levels of only a 
few positive cell cycle regulators, including Ccnd1, Ccnd2, Ccne1, Cdc16, E2f3 and Sertad1 
(Fig. 3C, and data not shown). These results suggest that impaired proliferation of ErbB2Cko 
CMs may result from derepression of genes that negatively regulate cell cycle progression.
Together, our data suggest that the expression level of ErbB2, which rapidly declines soon 
after birth, is positively associated with neonatal CM proliferation possibly through its role 
in repressing a set of negative cell cycle regulators.
4. Discussion
The mammalian CMs exit cell cycle shortly after birth and retain limited proliferative 
potential, thereby rendering the adult hearts incapable to regenerate after myocardial insults, 
and consequently develop heart failure (Fig. 1A). In contrast, in response to cardiac injury 
CMs of the lower vertebrates and neonatal mammalian hearts re-enter cell cycle and actively 
proliferate to restore lost myocardium and myocardial function (Poss, 2010). Though efforts 
have been made to stimulate existing adult CMs to re-enter cell cycle and proliferate for 
regenerative purposes (Reiss et al., 1996; Liao et al., 2001; Bersell et al., 2009; Sdek et al., 
2011; Mahmoud et al., 2013; Xin et al., 2013; Puente et al., 2014; D’Uva et al., 2015; 
Gemberling et al., 2015), mechanistic insight into the loss of proliferative potential of the 
adult mammalian CMs is still lacking. Herein, we provided evidence that ErbB2 expression 
is dramatically downregulated in the murine heart soon after birth (Fig. 1B, D). We further 
demonstrate that conditional cardiac ablation of ErbB2 resulted in a significant reduction in 
neonatal CM proliferation (Fig. 2B–E), which is accompanied with an overall significant 
upregulation of negative cell cycle regulators (Fig. 3A–B). Thus, our study suggests that the 
reduction in cardiac ErbB2 expression may be one of the contributing factors to the loss of 
postnatal CM proliferative capacity. It has been well documented that ErbB2 is an orphan 
receptor that heterodimerizes with other ErbB receptors, such as ErbB3 and ErbB4 to exert 
its biological functions (Brennan et al., 2000). During cardiac development, ErbB3 is mainly 
required for valvulogenesis but not any other aspects of cardiac development, including CM 
proliferation (Camenisch et al., 2002). In addition, the expression of ErbB3 is not detectable 
in neonatal hearts (Zhao et al., 1998), which is in sharp contrast to that of ErbB2 and ErbB4. 
Therefore, ErbB2/4 likely form heterodimer to regulate proliferation in neonatal CMs.
Previous studies have suggested that administration of recombinant Nrg1 improves cardiac 
function of injured hearts. This beneficial effect of Nrg1 can be attributed at least in part to 
its role in promoting CM proliferation after cardiac injury. Since ablating ErbB4 
significantly diminished the proliferative effects of Nrg1 (Bersell et al., 2009; D’Uva et al., 
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2015; Gemberling et al., 2015), reduced activities or expression levels of ErbB4/2 in the 
adult heart could limit a potentially greater beneficial effect of Nrg1. Indeed, we and others 
found that the expression of ErbB2 in the heart decreases over time until it reaches a 
relatively low level in the adult heart (Fig. 1B, D) (Lee et al., 1995; Zhao et al., 1998). More 
interestingly, the expression profile of ErbB2 in the neonatal heart correlates nicely with the 
heart transitioning from being regenerative to non-regenerative. Functionally, ablating ErbB2 
resulted in a significant reduction in neonatal CM proliferation (Fig. 2B–E). In contrast, 
overexpressing a constitutively active form of ErbB2 led to extensive proliferation of both 
neonatal and adult CMs, and appear to have a great effect on promoting CM proliferation 
than administration of recombinant NRG1 (D’Uva et al., 2015) (Bersell et al., 2009). 
Overall, our study provided clear evidence that ErbB2 is one of the important regulators of 
CM proliferation, and the downregulation of its postnatal expression correlates with the 
decline of CM proliferation. Thus, identifying the factors or pathways that downregulate 
ErbB2 expression in the adult heart may provide novel avenues to improve the therapeutic 
potential of recombinant NRG1.
5. Conclusion
The data provided here suggest that the steep decline in ErbB2 expression postnatally may 
account for the decreased cardiac proliferative capacity soon after birth. Yet, it still remains 
to be determined the molecular mechanism that downregulate cardiac ErbB2 expression 
after birth.
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Fig. 1. 
The expression profile of ErbB2 in the heart correlates with cardiac proliferative capacity. 
(A) A schematic illustration showing the difference of cardiac proliferative capacity over 
time. (B) qRT-PCR analysis of ErbB2, ErbB4, Nrg1 mRNA expression in murine hearts of 
different ages. (C) The relative expression of ErbB4 to ErbB2 from late embryonic to adult 
stages. (D) Western blots and quantification of ErbB2 protein expression in postnatal murine 
hearts. GADPH is used as a loading control. Data are presented as mean ± SEM. Statistical 
significance was determined by ANOVA test. *p < 0.05, **p < 0.01.
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Fig. 2. 
ErbB2 is required to neonatal CM proliferation. (A) qRT-PCR to determine the expression 
level of ErbB2 in CMs from ErbB2Cko. (B) Immunofluorescence analysis of CM 
proliferation of the ErbB2fl/fl and ErbB2Cko neonatal hearts by double staining of Ki67 
(green) and cTnT (Red) on P0. Representative images obtained under 10× and 40× 
magnification respectively. (C) Quantification of immunofluorescence analysis in (B). (D) 
Immunofluorescence analysis of CM karyokinesis of the ErbB2fl/fl and ErbB2Cko hearts by 
double staining of pH 3 (green) and cTnT (Red) at P0. Representative images obtained 
under 10× and 40× magnification respectively. (E) Quantification of immunofluorescence 
analysis in (D). Data are presented as mean ± SEM. Statistical significance was determined 
by student’s t-test (between two groups). *p < 0.05, **p < 0.01.
Ma et al. Page 10
Gene. Author manuscript; available in PMC 2017 March 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 3. 
ErbB2 ablation results in an upregulation in the expression of the negative cell cycle 
regulators. (A) qRT-PCR analysis of the expression of selected CDKIs in ErbB2fl/fl and 
ErbB2Cko CMs at P0. (B) qRT-PCR analysis of the expression of negative regulators of cell 
cycle in ErbB2fl/fl and ErbB2Cko CMs at P0. (C) qRT-PCR analysis of the expression of 
positive regulators of cell cycle in ErbB2fl/fl and ErbB2Cko CMs at P0. Data are presented as 
mean ± SEM. Statistical significance was determined by student’s t-test (between two 
groups). *p < 0.05, **p < 0.01.
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